{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:45:19Z","timestamp":1792273519531,"version":"4.4.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Multiple myeloma (MM) is a haematological malignancy characterised by high genomic heterogeneity. One of the most common cytogenic abnormalities in MM is the gain of genetic material at the long arm (q) of chromosome 1 (+\u20091q). While many mechanisms of resistance have been associated with +\u20091q alterations (e.g. CD38 downregulation, impairment of complement-dependent cytotoxicity, or induction of immunosuppression), the precise genetic or pathogenetic factors responsible for these alterations are still being investigated. Although interphase fluorescence in situ hybridisation (iFISH) is the gold standard for the detection of +\u20091q abnormalities used by the majority of diagnostic laboratories worldwide, there are no universally recognised cut-offs for +\u20091q positivity or a threshold for clinical meaningfulness. Because iFISH alone is insufficient to elucidate the extent of +\u20091q and other cytogenetic abnormalities in MM, sequencing-based methods could be adopted. The second revision of the international staging system for MM recently recognised\u2009+\u20091q as a high-risk feature. There is increasing evidence that +\u20091q has a prognostic value and influences the duration of remission, suggesting that patients with MM and +\u20091q may benefit from tailored therapy. This review comprehensively summarises the most recent biological evidence and clinical data on +\u20091q abnormalities in MM. However, given the heterogeneous data available, it remains difficult to draw firm conclusions. In clinical practice, +1q alterations should be evaluated along with other cytogenetic abnormalities and other biological and clinical characteristics of the disease. Ongoing and future studies will help the full understanding of the role of +\u20091q in MM.<\/jats:p>","DOI":"10.1007\/s00277-025-06212-5","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:54:56Z","timestamp":1739426096000},"page":"1443-1458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1711-6996","authenticated-orcid":false,"given":"Mattia","family":"D\u2019Agostino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-8707","authenticated-orcid":false,"given":"Marina","family":"Martello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7488-8247","authenticated-orcid":false,"given":"Lorenzo","family":"De Paoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9787-3083","authenticated-orcid":false,"given":"Silvia","family":"Mangiacavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0997-4157","authenticated-orcid":false,"given":"Daniele","family":"Derudas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4187-8912","authenticated-orcid":false,"given":"Francesca","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-3241","authenticated-orcid":false,"given":"Anna","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0948-9343","authenticated-orcid":false,"given":"Carmine","family":"Liberatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4813-8618","authenticated-orcid":false,"given":"Giuseppe","family":"Mele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8144-541X","authenticated-orcid":false,"given":"Roberto","family":"Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1515-0090","authenticated-orcid":false,"given":"Roberto","family":"Ria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-7305","authenticated-orcid":false,"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"6212_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV et al (2017) Multiple myeloma. Nat Rev Dis Primers 3:17046. https:\/\/doi.org\/10.1038\/nrdp.2017.46","journal-title":"Nat Rev Dis Primers"},{"key":"6212_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41571-021-00593-y","volume":"19","author":"AK Dutta","year":"2022","unstructured":"Dutta AK, Alberge JB, Sklavenitis-Pistofidis R, Lightbody ED, Getz G, Ghobrial IM (2022) Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine. Nat Rev Clin Oncol 19:223\u2013236. https:\/\/doi.org\/10.1038\/s41571-021-00593-y","journal-title":"Nat Rev Clin Oncol"},{"key":"6212_CR3","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.3390\/ijms20051248","volume":"20","author":"L Rasche","year":"2019","unstructured":"Rasche L, Kortum KM, Raab MS, Weinhold N (2019) The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma. Int J Mol Sci 20:1248. https:\/\/doi.org\/10.3390\/ijms20051248","journal-title":"Int J Mol Sci"},{"key":"6212_CR4","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3390\/diagnostics11091534","volume":"11","author":"A Salomon-Perzynski","year":"2021","unstructured":"Salomon-Perzynski A, Jamroziak K, Glodkowska-Mrowka E (2021) Clonal evolution of multiple myeloma-clinical and diagnostic implications. Diagnostics (Basel) 11:1534. https:\/\/doi.org\/10.3390\/diagnostics11091534","journal-title":"Diagnostics (Basel)"},{"key":"6212_CR5","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1182\/blood-2023-191065","volume":"142","author":"A McPherson","year":"2023","unstructured":"McPherson A, Maclachlan KH, Myers M, Satas G, Landgren O, Usmani SZ et al (2023) Single cell whole genome measurement of genomic heterogeneity and clonal evolution in multiple myeloma. Blood 142:4722. https:\/\/doi.org\/10.1182\/blood-2023-191065","journal-title":"Blood"},{"key":"6212_CR6","first-page":"953","volume":"26","author":"Y Marzin","year":"2006","unstructured":"Marzin Y, Jamet D, Douet-Guilbert N, Morel F, Le Bris MJ, Morice P et al (2006) Chromosome 1 abnormalities in multiple myeloma. Anticancer Res 26:953\u2013959","journal-title":"Anticancer Res"},{"key":"6212_CR7","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3324\/haematol.2014.103853","volume":"99","author":"S Caltagirone","year":"2014","unstructured":"Caltagirone S, Ruggeri M, Aschero S, Gilestro M, Oddolo D, Gay F et al (2014) Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. Haematologica 99:1611\u20131617. https:\/\/doi.org\/10.3324\/haematol.2014.103853","journal-title":"Haematologica"},{"key":"6212_CR8","doi-asserted-by":"crossref","unstructured":"Hassan H, Szalat R (2021) Genetic predictors of mortality in patients with multiple myeloma. Appl Clin Genet 14:241\u2013\u200954. https:\/\/www.doi.org\/10.2147\/TACG.S262866","DOI":"10.2147\/TACG.S262866"},{"key":"6212_CR9","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1182\/blood.2022017863","volume":"141","author":"A Schavgoulidze","year":"2023","unstructured":"Schavgoulidze A, Talbot A, Perrot A, Cazaubiel T, Leleu X, Manier S et al (2023) Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic Del(1p32) remains a strong prognostic factor. Blood 141:1308\u20131315. https:\/\/doi.org\/10.1182\/blood.2022017863","journal-title":"Blood"},{"key":"6212_CR10","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/S2152-2650(21)02127-3","volume":"21","author":"M D\u2019Agostino","year":"2021","unstructured":"D\u2019Agostino M, Belotti A, Zamagni E, Auclair D, Zambello R, Arigoni M et al (2021) OAB-055: Gain and amplification of 1q induce transcriptome deregulation and worsen the outcome of newly diagnosed multiple myeloma patients (18th International Myeloma Workshop Abstract). Clin Lymphoma Myeloma Leuk 21:S34. https:\/\/doi.org\/10.1016\/S2152-2650(21)02127-3","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6212_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","volume":"11","author":"TM Schmidt","year":"2021","unstructured":"Schmidt TM, Fonseca R, Usmani SZ (2021) Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J 11:83. https:\/\/doi.org\/10.1038\/s41408-021-00474-8","journal-title":"Blood Cancer J"},{"key":"6212_CR12","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC et al (2016) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127:2955\u20132962. https:\/\/doi.org\/10.1182\/blood-2016-01-631200","journal-title":"Blood"},{"key":"6212_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41408-023-00973-w","volume":"14","author":"O Pasvolsky","year":"2024","unstructured":"Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q et al (2024) Outcomes of patients with multiple myeloma and 1q gain\/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J 14:4. https:\/\/doi.org\/10.1038\/s41408-023-00973-w","journal-title":"Blood Cancer J"},{"key":"6212_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-024-01075-x","volume":"14","author":"M D\u2019Agostino","year":"2024","unstructured":"D\u2019Agostino M, Rota-Scalabrini D, Belotti A, Bertamini L, Arigoni M, De Sabbata G et al (2024) Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells. Blood Cancer J 14:94. https:\/\/doi.org\/10.1038\/s41408-024-01075-x","journal-title":"Blood Cancer J"},{"key":"6212_CR15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/17474086.2021.1983427","volume":"14","author":"K Bisht","year":"2021","unstructured":"Bisht K, Walker B, Kumar SK, Spicka I, Moreau P, Martin T et al (2021) Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. Expert Rev Hematol 14:1099\u20131114. https:\/\/doi.org\/10.1080\/17474086.2021.1983427","journal-title":"Expert Rev Hematol"},{"key":"6212_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/cancers13020256","volume":"13","author":"I Hanamura","year":"2021","unstructured":"Hanamura I (2021) Gain\/amplification of chromosome arm 1q21 in multiple myeloma. Cancers (Basel) 13:256. https:\/\/doi.org\/10.3390\/cancers13020256","journal-title":"Cancers (Basel)"},{"key":"6212_CR17","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1182\/blood.2022017010","volume":"141","author":"N Ansari-Pour","year":"2023","unstructured":"Ansari-Pour N, Samur M, Flynt E, Gooding S, Towfic F, Stong N et al (2023) Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed\/refractory myeloma. Blood 141:620\u2013633. https:\/\/doi.org\/10.1182\/blood.2022017010","journal-title":"Blood"},{"key":"6212_CR18","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1182\/blood-2023-182267","volume":"142","author":"F Maura","year":"2023","unstructured":"Maura F, Kaddoura M, Poos AM, Cirrincione A, Diamond B, Maclachlan KH et al (2023) The temporal evolution of chromosome 1q gain and hyperdiploidy and its impact on clinical outcomes in multiple myeloma. Blood 142:638. https:\/\/doi.org\/10.1182\/blood-2023-182267","journal-title":"Blood"},{"key":"6212_CR19","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.1158\/1078-0432.Ccr-20-4366","volume":"27","author":"B Ziccheddu","year":"2021","unstructured":"Ziccheddu B, Da Vi\u00e0 MC, Lionetti M, Maeda A, Morlupi S, Dugo M et al (2021) Functional impact of genomic complexity on the transcriptome of multiple myeloma. Clin Cancer Res 27:6479\u20136490. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-4366","journal-title":"Clin Cancer Res"},{"key":"6212_CR20","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-22-3209","volume":"29","author":"EM Boyle","year":"2023","unstructured":"Boyle EM, Blaney P, Stoeckle JH, Wang Y, Ghamlouch H, Gagler D et al (2023) Multiomic mapping of acquired chromosome 1 copy-number and structural variants to identify therapeutic vulnerabilities in multiple myeloma. Clin Cancer Res 29:3901\u20133913. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3209","journal-title":"Clin Cancer Res"},{"key":"6212_CR21","doi-asserted-by":"publisher","first-page":"20332","DOI":"10.1002\/cam4.6619","volume":"12","author":"K Bisht","year":"2023","unstructured":"Bisht K, Fukao T, Chiron M, Richardson P, Atanackovic D, Chini E et al (2023) Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma. Cancer Med 12:20332\u201320352. https:\/\/doi.org\/10.1002\/cam4.6619","journal-title":"Cancer Med"},{"key":"6212_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/14712598.2024.2357382","volume":"24","author":"E Barbieri","year":"2024","unstructured":"Barbieri E, Martino EA, Rivolti E, Quaresima M, Vigna E, Neri A et al (2024) Anti-CD38 monoclonal antibodies in multiple myeloma with gain\/amplification of chromosome arm 1q: a review of the literature. Expert Opin Biol Ther 24:365\u2013381. https:\/\/doi.org\/10.1080\/14712598.2024.2357382","journal-title":"Expert Opin Biol Ther"},{"key":"6212_CR23","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","volume":"11","author":"C Zhu","year":"2020","unstructured":"Zhu C, Song Z, Wang A, Srinivasan S, Yang G, Greco R et al (2020) Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells. Front Immunol 11:1771. https:\/\/doi.org\/10.3389\/fimmu.2020.01771","journal-title":"Front Immunol"},{"key":"6212_CR24","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284169","author":"L Notarfranchi","year":"2023","unstructured":"Notarfranchi L, Accardi F, Mancini C, Martella E, Bonomini S, Segreto R et al (2023) CD38 expression by plasma cells in extramedullary multiple myeloma. Haematologica: 1297\u2013 300. https:\/\/doi.org\/10.3324\/haematol.2023.284169","journal-title":"Haematologica:1297\u2013 300"},{"key":"6212_CR25","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3324\/haematol.2019.221176","volume":"105","author":"PJ Teoh","year":"2020","unstructured":"Teoh PJ, Chung TH, Chng PYZ, Toh SHM, Chng WJ (2020) IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification. Haematologica 105:1391\u20131404. https:\/\/doi.org\/10.3324\/haematol.2019.221176","journal-title":"Haematologica"},{"key":"6212_CR26","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1182\/blood-2023-173494","volume":"142","author":"W Kuroki","year":"2023","unstructured":"Kuroki W, Kitadate A, Yamada M, Iwama S, Takahashi Y, Fujioka Y et al (2023) Multiple myeloma with 1q gain\/amplification shows reduced CD38 expression via IL-6R overexpression. Blood 142:637. https:\/\/doi.org\/10.1182\/blood-2023-173494","journal-title":"Blood"},{"key":"6212_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/cells9010167","volume":"9","author":"I Saltarella","year":"2020","unstructured":"Saltarella I, Desantis V, Melaccio A, Solimando AG, Lamanuzzi A, Ria R et al (2020) Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma. Cells 9:167. https:\/\/doi.org\/10.3390\/cells9010167","journal-title":"Cells"},{"key":"6212_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bjh.16292","volume":"189","author":"M Mohan","year":"2020","unstructured":"Mohan M, Weinhold N, Schinke C, Thanedrarajan S, Rasche L, Sawyer JR et al (2020) Daratumumab in high-risk relapsed\/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain\/amplification and GEP70 status on outcome. Br J Haematol 189:67\u201371. https:\/\/doi.org\/10.1111\/bjh.16292","journal-title":"Br J Haematol"},{"key":"6212_CR29","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","volume":"128","author":"IS Nijhof","year":"2016","unstructured":"Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K et al (2016) CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood 128:959\u2013970. https:\/\/doi.org\/10.1182\/blood-2016-03-703439","journal-title":"Blood"},{"key":"6212_CR30","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1182\/blood.2019004332","volume":"136","author":"D Ogiya","year":"2020","unstructured":"Ogiya D, Liu J, Ohguchi H, Kurata K, Samur MK, Tai YT et al (2020) The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. Blood 136:2334\u20132345. https:\/\/doi.org\/10.1182\/blood.2019004332","journal-title":"Blood"},{"key":"6212_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/bjh.19088","volume":"203","author":"J Xu","year":"2023","unstructured":"Xu J, Wang Y, Li P, Chen C, Jiang Z, Wang X et al (2023) PRUNE1 (located on chromosome 1q21.3) promotes multiple myeloma with 1q21 gain by enhancing the links between purine and mitochondrion. Br J Haematol 203:599\u2013613. https:\/\/doi.org\/10.1111\/bjh.19088","journal-title":"Br J Haematol"},{"key":"6212_CR32","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1182\/blood.2021014391","volume":"139","author":"N Trasanidis","year":"2022","unstructured":"Trasanidis N, Katsarou A, Ponnusamy K, Shen YA, Kostopoulos IV, Bergonia B et al (2022) Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma. Blood 139:1939\u20131953. https:\/\/doi.org\/10.1182\/blood.2021014391","journal-title":"Blood"},{"key":"6212_CR33","doi-asserted-by":"publisher","unstructured":"Xu J, Wang Y, Ren L, Li P, Liu P (2024) IGF2BP1 promotes multiple myeloma with chromosome 1q gain via increasing CDC5L expression in an m6A-dependent manner. https:\/\/doi.org\/10.1016\/j.gendis.2024.101214. Genes Dis:101214","DOI":"10.1016\/j.gendis.2024.101214"},{"key":"6212_CR34","doi-asserted-by":"publisher","unstructured":"Xu J, Liu P (2023) IGF2BP1 promotes multiple myeloma with chromosome 1q gain via increasing CDC5L expression in an m6A-dependent manner. https:\/\/doi.org\/10.1182\/blood-2023-185888. Blood 142:1929","DOI":"10.1182\/blood-2023-185888"},{"key":"6212_CR35","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41467-024-45000-z","volume":"15","author":"C Terragna","year":"2024","unstructured":"Terragna C, Poletti A, Solli V, Martello M, Zamagni E, Pantani L et al (2024) Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in multiple myeloma patients with specific genomic, transcriptional and adverse clinical features. Nat Commun 15:1551. https:\/\/doi.org\/10.1038\/s41467-024-45000-z","journal-title":"Nat Commun"},{"key":"6212_CR36","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","volume":"97","author":"FM Ross","year":"2012","unstructured":"Ross FM, Avet-Loiseau H, Ameye G, Guti\u00e9rrez NC, Liebisch P, O\u2019Connor S et al (2012) Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 97:1272\u20131277. https:\/\/doi.org\/10.3324\/haematol.2011.056176","journal-title":"Haematologica"},{"key":"6212_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fonc.2020.00189","volume":"10","author":"N Bolli","year":"2020","unstructured":"Bolli N, Genuardi E, Ziccheddu B, Martello M, Oliva S, Terragna C (2020) Next-generation sequencing for clinical management of multiple myeloma: ready for prime time? Front Oncol 10:189. https:\/\/doi.org\/10.3389\/fonc.2020.00189","journal-title":"Front Oncol"},{"key":"6212_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s42649-021-00053-y","volume":"51","author":"Z Frankenstein","year":"2021","unstructured":"Frankenstein Z, Uraoka N, Aypar U, Aryeequaye R, Rao M, Hameed M et al (2021) Automated 3D scoring of fluorescence in situ hybridization (FISH) using a confocal whole slide imaging scanner. Appl Microsc 51:4. https:\/\/doi.org\/10.1186\/s42649-021-00053-y","journal-title":"Appl Microsc"},{"key":"6212_CR39","doi-asserted-by":"publisher","first-page":"e0285696","DOI":"10.1371\/journal.pone.0285696","volume":"18","author":"A Marx","year":"2023","unstructured":"Marx A, Osvath M, Szikora B, Pipek O, Csabai I, Nagy A et al (2023) Liquid biopsy-based monitoring of residual disease in multiple myeloma by analysis of the rearranged immunoglobulin genes-A feasibility study. PLoS ONE 18:e0285696. https:\/\/doi.org\/10.1371\/journal.pone.0285696","journal-title":"PLoS ONE"},{"key":"6212_CR40","doi-asserted-by":"publisher","unstructured":"Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842\u2013854. https:\/\/doi.org\/10.1002\/1097-0142(197509)36:3%3C842::aid-cncr2820360303%3E3.0.co;2-u.","DOI":"10.1002\/1097-0142(197509)36:3%3C842::aid-cncr2820360303%3E3.0.co;2-u."},{"key":"6212_CR41","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A et al (2022) Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY Project. J Clin Oncol 40:3406\u20133418. https:\/\/doi.org\/10.1200\/JCO.21.02614","journal-title":"J Clin Oncol"},{"key":"6212_CR42","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412\u20133420. https:\/\/doi.org\/10.1200\/JCO.2005.04.242","journal-title":"J Clin Oncol"},{"key":"6212_CR43","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al (2015) Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 33:2863\u20132869. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267","journal-title":"J Clin Oncol"},{"key":"6212_CR44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","volume":"12","author":"P Hagen","year":"2022","unstructured":"Hagen P, Zhang J, Barton K (2022) High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer J 12:83. https:\/\/doi.org\/10.1038\/s41408-022-00679-5","journal-title":"Blood Cancer J"},{"key":"6212_CR45","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Multiple Myeloma V.4.2024 \u00a9 National Comprehensive Cancer Network, Inc (2024) All rights reserved. Accessed on July26, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way"},{"key":"6212_CR46","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G et al (2021) Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 32:309\u2013322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014","journal-title":"Ann Oncol"},{"key":"6212_CR47","unstructured":"mSMART (2023) Treatment Guidelines: Multiple Myeloma. https:\/\/www.msmart.org\/mm-treatment-guidelines. Accessed 14 June 2024"},{"key":"6212_CR48","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","volume":"4","author":"N Abdallah","year":"2020","unstructured":"Abdallah N, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB et al (2020) Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv 4:3509\u20133519. https:\/\/doi.org\/10.1182\/bloodadvances.2020002218","journal-title":"Blood Adv"},{"key":"6212_CR49","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.26639","volume":"97","author":"E Kastritis","year":"2022","unstructured":"Kastritis E, Migkou M, Dalampira D, Gavriatopoulou M, Fotiou D, Roussou M et al (2022) Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications. Am J Hematol 97:1142\u20131149. https:\/\/doi.org\/10.1002\/ajh.26639","journal-title":"Am J Hematol"},{"key":"6212_CR50","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/leu.2017.179","volume":"32","author":"V Shah","year":"2018","unstructured":"Shah V, Sherborne AL, Walker BA, Johnson DC, Boyle EM, Ellis S et al (2018) Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia 32:102\u2013110. https:\/\/doi.org\/10.1038\/leu.2017.179","journal-title":"Leukemia"},{"key":"6212_CR51","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/S2152-2650(21)02126-1","volume":"21","author":"P Kapoor","year":"2021","unstructured":"Kapoor P, Schmidt T, Jacobus S, Wei Z, Fonseca R, Callander NS et al (2021) OAB-052: impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trial. Clin Lymphoma Myeloma Leuk 21:S33\u2013S34. https:\/\/doi.org\/10.1016\/S2152-2650(21)02126-1","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6212_CR52","unstructured":"Raab MS, Mai EK, Bertsch U, Fenk R, Pozeck E, Benner A et al (2024) Isatuximab, lenalidomide, bortezomib and dexamethasone for newly-diagnosed, transplant-eligible multiple myeloma: post transplantation interim analysis of the randomized phase III GMMG-HD7 trial (EHA2024 Congress abstract S202). https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/422306\/marc.s.raab.isatuximab.lenalidomide.bortezomib.and.dexamethasone.for.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2552%2Aot_id%3D29201%2Amarker%3D5099%2Afeatured%3D18527. Accessed 4 July 2024"},{"key":"6212_CR53","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.21.01393","volume":"40","author":"L Bertamini","year":"2022","unstructured":"Bertamini L, Oliva S, Rota-Scalabrini D, Paris L, More S, Corradini P et al (2022) High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. J Clin Oncol 40:3120\u20133131. https:\/\/doi.org\/10.1200\/JCO.21.01393","journal-title":"J Clin Oncol"},{"key":"6212_CR54","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"F Gay","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M et al (2021) Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol 22:1705\u20131720. https:\/\/doi.org\/10.1016\/S1470-2045(21)00535-0","journal-title":"Lancet Oncol"},{"key":"6212_CR55","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","volume":"24","author":"R Mina","year":"2023","unstructured":"Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A et al (2023) Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncol 24:64\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(22)00693-3","journal-title":"Lancet Oncol"},{"key":"6212_CR56","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C et al (2020) Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136:936\u2013945. https:\/\/doi.org\/10.1182\/blood.2020005288","journal-title":"Blood"},{"key":"6212_CR57","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C et al (2023) Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 10:e825\u2013e837. https:\/\/doi.org\/10.1016\/S2352-3026(23)00217-X","journal-title":"Lancet Haematol"},{"key":"6212_CR58","doi-asserted-by":"publisher","unstructured":"Facon T, Dimopoulos M-A, Leleu XP, Beksac M, Pour L, H\u00e1jek R et al (2024) Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. https:\/\/doi.org\/10.1056\/NEJMoa2400712. NEJM","DOI":"10.1056\/NEJMoa2400712"},{"key":"6212_CR59","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1200\/JCO.22.02567","volume":"41","author":"MF Kaiser","year":"2023","unstructured":"Kaiser MF, Hall A, Walker K, Sherborne A, De Tute RM, Newnham N et al (2023) Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma. J Clin Oncol 41:3945\u20133955. https:\/\/doi.org\/10.1200\/JCO.22.02567","journal-title":"J Clin Oncol"},{"key":"6212_CR60","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1182\/blood-2023-177896","volume":"142","author":"MF Kaiser","year":"2023","unstructured":"Kaiser MF, Phillip R, Hall A, Holroyd A, Bevington L, de Tute RM et al (2023) Ultra high-risk multiple myeloma patients with multi-hit tumours and SKY92 high risk signature are at increased risk of early relapse even when treated with extended intensified induction and consolidation - results from the OPptimum\/Muknine trial. Blood 142:881. https:\/\/doi.org\/10.1182\/blood-2023-177896","journal-title":"Blood"},{"key":"6212_CR61","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N et al (2019) Daratumumab plus Lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 380:2104\u20132115. https:\/\/doi.org\/10.1056\/NEJMoa1817249","journal-title":"N Engl J Med"},{"key":"6212_CR62","unstructured":"Facon T, Kumar S, Orlowski RZ, Bahlis NJ, Moreau P, Goldschmidt H et al (2024) Final survival analysis of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: MAIA study (EHA2024 Congress abstract P968). https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/421032\/thierry.facon.final.survival.analysis.of.daratumumab.plus.lenalidomide.and.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3D%23p968. Accessed 3 July 2024"},{"key":"6212_CR63","doi-asserted-by":"crossref","unstructured":"Moreau P, Facon T, Usmani SZ, Bahlis N, Raje N, Plesner T et al Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): clinical assessment of key subgroups of the phase 3 MAIA study [poster 3245]. 64th American Society of Hematology (ASH) Annual Meeting & Exposition; December 10\u201313, 2022; New Orleans, LA, USA2022","DOI":"10.1182\/blood-2022-163494"},{"key":"6212_CR64","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I et al (2019) Isatuximab plus Pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 394:2096\u20132107. https:\/\/doi.org\/10.1016\/S0140-6736(19)32556-5","journal-title":"Lancet"},{"key":"6212_CR65","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/bjh.17499","volume":"194","author":"SJ Harrison","year":"2021","unstructured":"Harrison SJ, Perrot A, Alegre A, Simpson D, Wang MC, Spencer A et al (2021) Subgroup analysis of ICARIA-MM study in relapsed\/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol 194:120\u2013131. https:\/\/doi.org\/10.1111\/bjh.17499","journal-title":"Br J Haematol"},{"key":"6212_CR66","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.3324\/haematol.2022.280660","volume":"107","author":"T Martin","year":"2022","unstructured":"Martin T, Richardson PG, Facon T, Moreau P, Perrot A, Spicka I et al (2022) Primary outcomes by 1q21\u2009+\u2009status for isatuximab-treated patients with relapsed\/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA. Haematologica 107:2485\u20132491. https:\/\/doi.org\/10.3324\/haematol.2022.280660","journal-title":"Haematologica"},{"key":"6212_CR67","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.2217\/fon-2019-0431","volume":"16","author":"P Moreau","year":"2020","unstructured":"Moreau P, Dimopoulos MA, Yong K, Mikhael J, Risse ML, Asset G et al (2020) Isatuximab plus carfilzomib\/dexamethasone versus carfilzomib\/dexamethasone in patients with relapsed\/refractory multiple myeloma: IKEMA Phase III study design. Future Oncol 16:4347\u20134358. https:\/\/doi.org\/10.2217\/fon-2019-0431","journal-title":"Future Oncol"},{"key":"6212_CR68","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2217\/fon-2017-0616","volume":"14","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, Attal M, Campana F, Le-Guennec S, Hui AM, Risse ML et al (2018) Isatuximab plus pomalidomide\/dexamethasone versus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma: ICARIA phase III study design. Future Oncol 14:1035\u20131047. https:\/\/doi.org\/10.2217\/fon-2017-0616","journal-title":"Future Oncol"},{"key":"6212_CR69","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/ajh.26261","volume":"96","author":"S Richard","year":"2021","unstructured":"Richard S, Chari A, Delimpasi S, Simonova M, Spicka I, Pour L et al (2021) Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by cytogenetic risk. Am J Hematol 96:1120\u20131130. https:\/\/doi.org\/10.1002\/ajh.26261","journal-title":"Am J Hematol"},{"key":"6212_CR70","doi-asserted-by":"publisher","first-page":"e7523284","DOI":"10.1097\/01.Hs9.0000970568.75232.84","volume":"7","author":"T Facon","year":"2023","unstructured":"Facon T, Moreau P, \u0160picka I, Suzuki K, Yong K, Mikhael J et al (2023) P916: long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21\u2009+\u2009status: updated results from the phase 3 IKEMA study. HemaSphere 7:e7523284. https:\/\/doi.org\/10.1097\/01.Hs9.0000970568.75232.84","journal-title":"HemaSphere"},{"key":"6212_CR71","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1097\/01.HS9.0000846548.89204.ce","volume":"6","author":"L Kuang","year":"2022","unstructured":"Kuang L, Fang B, Chen W, Liu A, Li C, Bao L et al (2022) P920: effectiveness and safety of selinexor-based regimen in the treatment of relapsed and refractory multiple myeloma: a multicenter real-world study from China. HemaSphere 6:810\u2013811. https:\/\/doi.org\/10.1097\/01.HS9.0000846548.89204.ce","journal-title":"HemaSphere"},{"key":"6212_CR72","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M et al (2018) Elotuzumab plus Pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 379:1811\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa1805762","journal-title":"N Engl J Med"},{"key":"6212_CR73","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1200\/jco.21.00972","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M et al (2021) Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 39:2430\u20132442. https:\/\/doi.org\/10.1200\/jco.21.00972","journal-title":"J Clin Oncol"},{"key":"6212_CR74","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00277-020-03985-9","volume":"99","author":"YC Cohen","year":"2020","unstructured":"Cohen YC, Magen H, Lavi N, Gatt ME, Chubar E, Horowitz N et al (2020) Ixazomib-based regimens for relapsed\/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study. Ann Hematol 99:1273\u20131281. https:\/\/doi.org\/10.1007\/s00277-020-03985-9","journal-title":"Ann Hematol"},{"key":"6212_CR75","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41408-024-00985-0","volume":"14","author":"K Neupane","year":"2024","unstructured":"Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R et al (2024) Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer J 14:20. https:\/\/doi.org\/10.1038\/s41408-024-00985-0","journal-title":"Blood Cancer J"},{"key":"6212_CR76","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C et al (2019) Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20:57\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(18)30687-9","journal-title":"Lancet Oncol"},{"key":"6212_CR77","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","volume":"119","author":"K Neben","year":"2012","unstructured":"Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B et al (2012) Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 119:940\u2013948. https:\/\/doi.org\/10.1182\/blood-2011-09-379164","journal-title":"Blood"},{"key":"6212_CR78","doi-asserted-by":"publisher","first-page":"e1003454","DOI":"10.1371\/journal.pmed.1003454","volume":"18","author":"GH Jackson","year":"2021","unstructured":"Jackson GH, Pawlyn C, Cairns DA, de Tute RM, Hockaday A, Collett C et al (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): interim analysis of an open-label randomised controlled trial. PLoS Med 18:e1003454. https:\/\/doi.org\/10.1371\/journal.pmed.1003454","journal-title":"PLoS Med"},{"key":"6212_CR79","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I et al (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373:621\u2013631. https:\/\/doi.org\/10.1056\/NEJMoa1505654","journal-title":"N Engl J Med"},{"key":"6212_CR80","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood.V116.21.40.40","volume":"116","author":"P Sonneveld","year":"2010","unstructured":"Sonneveld P, Schmidt-Wolf I, van der Holt B, Jarari Le, Bertsch U, Salwender H et al (2010) HOVON-65\/GMMG-HD4 randomized Phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Blood 116:40. https:\/\/doi.org\/10.1182\/blood.V116.21.40.40","journal-title":"Blood"},{"key":"6212_CR81","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1182\/blood-2023-173896","volume":"142","author":"KJC Lim","year":"2023","unstructured":"Lim KJC, Wellard C, Moore E, Ninkovic S, Chng W-J, Spencer A et al (2023) Impact of 1q21 gain and amplification on daratumumab-treated multiple myeloma patients: real-world data from the Australia-New Zealand and Asia-Pacific myeloma and related diseases registries. Blood 142:3325. https:\/\/doi.org\/10.1182\/blood-2023-173896","journal-title":"Blood"},{"key":"6212_CR82","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1007\/s00277-022-04978-6","volume":"101","author":"E Barbieri","year":"2022","unstructured":"Barbieri E, Maccaferri M, Leonardi G, Giacobbi F, Corradini G, Lagreca I et al (2022) Adverse outcome associated with daratumumab-based treatments in relapsed\/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience. Ann Hematol 101:2777\u20132779. https:\/\/doi.org\/10.1007\/s00277-022-04978-6","journal-title":"Ann Hematol"},{"key":"6212_CR83","doi-asserted-by":"publisher","first-page":"7237","DOI":"10.1182\/blood-2022-169533","volume":"140","author":"RD Parrondo","year":"2022","unstructured":"Parrondo RD, Gardner LB, Alhaj Moustafa M, Roy V, Sher T, Rasheed A et al (2022) Therapeutic outcomes of relapsed-refractory multiple myeloma patients with 1q21\u2009+\u2009treated with daratumumab-based regimens: a retrospective analysis. Blood 140:7237\u20137238. https:\/\/doi.org\/10.1182\/blood-2022-169533","journal-title":"Blood"},{"key":"6212_CR84","first-page":"4438","volume":"11","author":"A Minguela","year":"2021","unstructured":"Minguela A, Vasco-Mogorron MA, Campillo JA, Cabanas V, Remigia MJ, Berenguer M et al (2021) Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment. Am J Cancer Res 11:4438\u20134454","journal-title":"Am J Cancer Res"},{"key":"6212_CR85","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1080\/10428194.2021.1948032","volume":"62","author":"M Shen","year":"2021","unstructured":"Shen M, Yang G, Li X, Geng C, Huang Z, Chen W (2021) At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China. Leuk Lymphoma 62:2992\u20133001. https:\/\/doi.org\/10.1080\/10428194.2021.1948032","journal-title":"Leuk Lymphoma"},{"key":"6212_CR86","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00277-020-04384-w","volume":"100","author":"S Oliva","year":"2021","unstructured":"Oliva S, De Paoli L, Ruggeri M, Caltagirone S, Troia R, Oddolo D et al (2021) A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS\/SMM to newly diagnosed and relapsed multiple myeloma. Ann Hematol 100:437\u2013443. https:\/\/doi.org\/10.1007\/s00277-020-04384-w","journal-title":"Ann Hematol"},{"key":"6212_CR87","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","volume":"108","author":"I Hanamura","year":"2006","unstructured":"Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR et al (2006) Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108:1724\u20131732. https:\/\/doi.org\/10.1182\/blood-2006-03-009910","journal-title":"Blood"},{"key":"6212_CR88","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1200\/jco.21.01987","volume":"41","author":"R Lannes","year":"2023","unstructured":"Lannes R, Samur M, Perrot A, Mazzotti C, Divoux M, Cazaubiel T et al (2023) In multiple myeloma, high-risk secondary genetic events observed at Relapse are Present from diagnosis in tiny, undetectable subclonal populations. J Clin Oncol 41:1695\u20131702. https:\/\/doi.org\/10.1200\/jco.21.01987","journal-title":"J Clin Oncol"},{"key":"6212_CR89","first-page":"27","volume":"107","author":"B Taurisano","year":"2022","unstructured":"Taurisano B (2022) Design and validation of a custom NGS targeted panel, MM-UMA (unique molecular assay)-panel, to identify genomic abnormalities in multiple myeloma patients: intra-laboratory validation. Haematologica 107:27","journal-title":"Haematologica"},{"key":"6212_CR90","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1182\/blood.2023023597","volume":"143","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, Perrot A, Hulin C, Manier S, Macro M, Chretien ML et al (2024) Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood 143:2029\u20132036. https:\/\/doi.org\/10.1182\/blood.2023023597","journal-title":"Blood"},{"key":"6212_CR91","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/jco.23.01696","volume":"42","author":"LB Leypoldt","year":"2024","unstructured":"Leypoldt LB, Tichy D, Besemer B, H\u00e4nel M, Raab MS, Mann C et al (2024) Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol 42:26\u201337. https:\/\/doi.org\/10.1200\/jco.23.01696","journal-title":"J Clin Oncol"},{"key":"6212_CR92","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.1182\/blood-2023-187453","volume":"142","author":"CSY Lecat","year":"2023","unstructured":"Lecat CSY, Chant A, McCourt O, Meads D, Cicero R, Royle K-L et al (2023) Health-Related Quality of Life (HRQoL) in patients with genetic standard and high-risk disease at Trial Entry: a cross-sectional analysis of RADAR (UK-MRA Myeloma XV). Blood 142:4710. https:\/\/doi.org\/10.1182\/blood-2023-187453","journal-title":"Blood"},{"key":"6212_CR93","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1182\/blood.2023022080","volume":"143","author":"M D\u2019Agostino","year":"2024","unstructured":"D\u2019Agostino M, Bertuglia G, Rota-Scalabrini D, Belotti A, Mor\u00e8 S, Corradini P et al (2024) Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma. Blood 143:592\u2013596. https:\/\/doi.org\/10.1182\/blood.2023022080","journal-title":"Blood"},{"key":"6212_CR94","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"H Goldschmidt","year":"2022","unstructured":"Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D et al (2022) Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol 9:e810\u2013e821. https:\/\/doi.org\/10.1016\/S2352-3026(22)00263-0","journal-title":"Lancet Haematol"},{"key":"6212_CR95","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/s2352-3026(20)30354-9","volume":"8","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita SF et al (2021) Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol 8:e45\u2013e54. https:\/\/doi.org\/10.1016\/s2352-3026(20)30354-9","journal-title":"Lancet Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06212-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06212-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06212-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:10:03Z","timestamp":1745575803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06212-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6212"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06212-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mattia D\u2019Agostino has received honoraria for lectures from GSK, Sanofi and Janssen; and has served on the advisory boards of GSK, Sanofi and Bristol Myers Squibb\/Celgene. Marina Martello has received honoraria from Takeda, Bristol Myers Squibb\/Celgene, Sanofi, Janssen and GSK. Lorenzo De Paoli has received honoraria from Janssen, Sanofi, GSK, Menarini, Amgen, AstraZeneca, BeiGene and AbbVie; and has served on the advisory boards of GSK, Menarini, Amgen and Janssen. Silvia Mangiacavalli has received honoraria from Janssen, Sanofi, GSK, Menarini and Pfizer; has served on the advisory boards of Janssen, Sanofi, Bristol Myers Squibb\/Celgene, GSK, Menarini and Takeda; and has received consultancy fees from Janssen. Daniele Derudas has received speaker fees from GSK, Johnson & Johnson, Bristol Myers Squibb\/Celgene, Takeda and Amgen. Francesca Fazio has received honoraria from Janssen and GSK; has served on the advisory boards of GSK; and has received consultancy fees from Janssen, Menarini and Amgen. Anna Furlan has served on the advisory boards of Janssen, Takeda, Menarini, Amgen, Sanofi and GSK; and has received honoraria from Janssen, Takeda, Sanofi, GSK and Bristol Myers Squibb\/Celgene. Carmine Liberatore has received honoraria from Janssen, Sanofi, GSK and Menarini; has served on advisory boards for Janssen, Sanofi, Bristol Myers Squibb\/Celgene, GSK, Amgen, Menarini and Takeda; and received consultancy fees from GSK. Giuseppe Mele has received honoraria from Janssen, Sanofi, Amgen, Menarini, Celgene and Takeda; and has served on advisory boards for Janssen, Amgen, Menarini and Bristol Myers Squibb\/Celgene. Roberto Mina has received honoraria from Janssen, Celgene, Takeda and Amgen; served on the advisory boards of Janssen, Takeda, Bristol Myers Squibb\/Celgene, Amgen and Pfizer; and has received consultancy fees from Janssen, Takeda and Sanofi. Roberto Ria has served on the speaker\u2019s bureau of Amgen, Bristol Myers Squibb\/Celgene, CSL Behring, Janssen Cilag, Octapharma and Takeda; and was a consultant for Amgen, Bristol Myers Squibb\/Celgene, CSL Behring, GSK, Janssen Cilag, Pfizer, Sanofi and Takeda. Elena Zamagni has received honoraria from and has served in an advisory role for Janssen, Bristol-Myers Squibb\/Celgene, Sanofi, Amgen, GSK, Pfizer, Oncopeptides and Menarini-Stemline.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}